Lacopat (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing these channels, it reduces the repetitive firing of neurons that can trigger seizures, thereby helping to control epileptic activity.

The specific dose of Lacopat is determined by the prescribing clinician based on the individual’s medical condition, age, renal function, and response to therapy. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for lacosamide in pregnancy and lactation are limited. The prescriber should weigh the potential benefits against possible risks and discuss alternative options if appropriate. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their doctor before using Lacopat.

To request Lacopat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lacopat (lacosamide) is distinct because it selectively enhances slow inactivation of sodium channels, whereas many other antiepileptics target fast inactivation or different pathways. This mechanism can offer efficacy in patients who have not responded to drugs with other mechanisms, but individual response varies.

Lacopat tablets should be stored at room temperature, below 25 °C, in the original packaging. Protect them from moisture, excessive heat, and direct sunlight to maintain product stability throughout its shelf life.

Lacopat is taken orally, usually as a tablet, with or without food. The exact administration schedule—once or twice daily—depends on the prescriber’s instructions and the patient’s therapeutic needs.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, and emergence or worsening of suicidal thoughts. Patients should be monitored regularly for these events, especially during treatment initiation.

Lacopat is contraindicated in individuals with known hypersensitivity to lacosamide or any of its excipients. Caution is also advised for patients with significant cardiac conduction disorders, severe hepatic impairment, or those taking medications that markedly affect its metabolism.